Велика Британія - англійська - MHRA (Medicines & Healthcare Products Regulatory Agency)

bristol-myers squibb pharmaceuticals ltd - didanosine - chewable tablet - 25mg

Велика Британія - англійська - MHRA (Medicines & Healthcare Products Regulatory Agency)

bristol-myers squibb pharmaceuticals ltd - dasatinib - tablet - 20mg

Велика Британія - англійська - MHRA (Medicines & Healthcare Products Regulatory Agency)

bristol-myers squibb pharmaceuticals ltd - dasatinib - tablet - 50mg

Велика Британія - англійська - MHRA (Medicines & Healthcare Products Regulatory Agency)

bristol-myers squibb pharmaceuticals ltd - dasatinib - tablet - 100mg

Велика Британія - англійська - MHRA (Medicines & Healthcare Products Regulatory Agency)

bristol-myers squibb pharmaceuticals ltd - dasatinib - tablet - 140mg

Велика Британія - англійська - MHRA (Medicines & Healthcare Products Regulatory Agency)

bristol-myers squibb pharmaceuticals ltd - dasatinib - tablet - 80mg

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - didanosine -

Велика Британія - англійська - MHRA (Medicines & Healthcare Products Regulatory Agency)

bristol-myers squibb pharmaceuticals ltd - hydrochlorothiazide; captopril - oral tablet - 25mg ; 50mg

Європейський Союз - англійська - EMA (European Medicines Agency)

bristol myers squibb pharma eeig - luspatercept - anemia; myelodysplastic syndromes; beta-thalassemia - other antianemic preparations - reblozyl is indicated for the treatment of adult patients with transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndromes (mds) with ring sideroblasts, who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy (see section 5.1).reblozyl is indicated in adults for the treatment of anaemia associated with transfusion dependent and non transfusion dependent beta thalassaemia (see section 5.1).

Ізраїль - англійська - Ministry of Health

bristol, myers squibb (israel) limited, israel - luspatercept - powder for solution for injection - luspatercept 25 mg - luspatercept - reblozyl is indicated for the treatment of adult patients with transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndromes (mds) with ring sideroblasts, who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy.reblozyl is indicated in adults for the treatment of anaemia associated with transfusion dependent and non-transfusion-dependent beta-thalassaemia